In addition, we found that the chimeric antigen receptor (CAR) for DLL3 has an antitumor effect in SCLC in mice, and thus therapies targeting CAR T cells for DLL3 may provide a new strategy for the treatment of SCLC (117). Here, DLL3 is linked to small cell lung carcinoma.